☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Ascendis Pharma
Ascendis Pharma’s Yorvipath Receives the US FDA’s Approval to Treat Hypoparathyroidism
August 12, 2024
Ascendis Pharma Receives MHRA Approval for YORVIPATH (Palopegteriparatide) Against Chronic Hypoparathyroidism in Great Britain
April 25, 2024
Ascendis Pharma Receives the EMA’s CHMP Positive Opinion of TransCon PTH (palopegteriparatide) for Chronic Hypoparathyroidism
September 15, 2023
Ascendis Pharma Presented One-Year P-III Trial (PaTHway) Results of TransCon PTH for Hypoparathyroidism at ENDO 2023
June 19, 2023
Ascendis Pharma Reports the US FDA’s Acceptance of NDA for Priority Review of TransCon PTH to Treat Hypoparathyroidism in Adult Pa...
November 1, 2022
Ascendis Pharma Reports Results of TransCon PTH in P-III (PaTHway) Trial for the Treatment of Hypoparathyroidism
March 14, 2022
Load more...
Back to Home